Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
# Background Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. # Study Question What is the effectiveness of rivaroxaban versus the standard of ca...
Збережено в:
| Автори: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Columbia Data Analytics, LLC
2019-10-01
|
| Серія: | Journal of Health Economics and Outcomes Research |
| Онлайн доступ: | https://doi.org/10.36469/9936 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|